Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Edwards Lifesciences on Friday, setting a price target of $130, which is approximately 16.47% above the...
Edwards Lifesciences (NYSE: EW), a cardio device company, reported Q2 earnings of $489.5 million, or $0.64, ahead of the consensus of $0.55."Vaccine adoption in key regions has...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
SPECIAL ALERT: Remember, we need your input to make next week’s new Zacks Ultimate Strategy Session episode the best it can be. There are two ways you can participate:1)...
Data from the China Passenger Car Association reveals that Tesla (NASDAQ:TSLA) started to recover from its April slump in sales. The automaker sold 33,463 cars in China last month,...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Buy | Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Buy | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 200.09 | 202.07 | 196.25 | +4.90 | +2.51% | 17.89M | NYSE | |||
| 2,697.10 | 2,706.70 | 2,675.90 | +2.6 | +0.10% | 1.08M | NASDAQ | |||
| 351.95 | 359.40 | 350.74 | -4.35 | -1.22% | 13.18M | NASDAQ | |||
| 28.98 | 30.29 | 28.81 | -0.21 | -0.72% | 3.00M | NASDAQ | |||
| 121.37 | 122.04 | 120.32 | +1.12 | +0.93% | 656.40K | NYSE | |||
| 197.50 | 199.61 | 193.61 | +2.51 | +1.29% | 21.74M | NASDAQ | |||
| 53.68 | 54.47 | 53.53 | -0.04 | -0.07% | 18.10M | NASDAQ | |||
| 204.30 | 211.46 | 203.79 | -1.16 | -0.56% | 326.26K | NYSE | |||
| 151.17 | 154.45 | 151.07 | -0.61 | -0.40% | 10.20M | NYSE | |||
| 29.92 | 31.79 | 29.92 | -1.31 | -4.19% | 4.83M | NYSE | |||
| 26.62 | 27.57 | 26.57 | -0.66 | -2.42% | 11.01M | NASDAQ | |||
| 23.36 | 23.83 | 22.97 | -0.29 | -1.23% | 5.07M | NYSE | |||
| 235.40 | 240.38 | 233.80 | -1.18 | -0.50% | 2.15M | NASDAQ | |||
| 125.91 | 126.82 | 125.09 | -1.19 | -0.94% | 1.23M | NASDAQ | |||
| 77.64 | 79.49 | 77.47 | +0.06 | +0.08% | 14.90M | NASDAQ |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
